Last reviewed · How we verify
NCT06747988
Feasibility and Prospective Study of a Dynamic Traction Device for Use During ESD
trial testing Traction Device in Gastrointestinal Neoplasms in 100 participants. Not yet recruiting.
30 March 2026
Quick facts
| Lead sponsor | Baylor College of Medicine |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 30 March 2025 |
| Primary completion | 30 March 2026 |
| Estimated completion | 20 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Traction Device
Conditions studied
- Gastrointestinal Neoplasms — all drugs for Gastrointestinal Neoplasms →
Sponsor
Baylor College of Medicine
Who can join
18 and older, any sex, with Gastrointestinal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this prospective study at Baylor St. Luke's Medical Center is to investigate the the efficacy and safety of using the novel TTS helix tack suture device as a dynamic traction device during colon and gastric endoscopic submucosal dissection (ESD). The investigators of this study hypothesize that a dynamic traction during ESD can be less traumatic than with other traction devices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06747988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Traction Device
Trials testing the same drug.
- NCT06159634 — Traction vs. No Traction in Colonic ESD · NA · recruiting
Other recruiting trials for Gastrointestinal Neoplasms
Currently open trials in the same condition.
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT07218926 — A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatini · Phase 3 · recruiting
- NCT07319364 — A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects · Phase 1 · recruiting
- NCT06885034 — A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advance · Phase 1, PHASE2 · recruiting
- NCT06996483 — Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastroin · recruiting
Other Baylor College of Medicine trials
Trials by the same sponsor.
- NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
- NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
- NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
- NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
- NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747988 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing